
Diabetic Neuropathic Pain Market
Description
Diabetic Neuropathic Pain Market Report and Forecast 2024-2032
The diabetic neuropathic pain market was valued at USD 4.3 billion in 2023 driven by the increasing demand for effective treatments that alleviate chronic pain and improve quality of life, alongside advancements in pain management therapies such as non-opioid drugs and neuromodulation devices. The market is projected to grow at a CAGR of 7.7% during the forecast period of 2024-2032, and likely to reach a market value of USD 8.5 billion by 2032.
Diabetic Neuropathic Pain Market Analysis
Diabetic neuropathic pain is a chronic and often debilitating condition caused by nerve damage resulting from prolonged high blood sugar levels in diabetic patients. It typically affects the feet, legs, and hands, and is characterised by burning, tingling, and sharp pain. This condition significantly impacts the quality of life, requiring long-term management through medications, physical therapy, and lifestyle adjustments.
Market Drivers
Rising Prevalence of Diabetes: The increasing prevalence of diabetes, particularly type 2 diabetes, is a major driver of the diabetic neuropathic pain market. As more people develop diabetes, the number of patients suffering from neuropathic complications is expected to rise, driving demand for effective treatments.
Advancements in Pain Management Therapies: Innovations in pain management, including the development of new drugs and non-invasive treatments, are contributing to market growth. Improved understanding of neuropathic pain pathways has led to more targeted therapies, enhancing treatment outcomes for diabetic neuropathic pain.
Growing Geriatric Population: The ageing population is more susceptible to diabetes and its complications, including neuropathic pain. As the elderly population increases, so too does the demand for effective treatments for diabetic neuropathic pain, particularly in developed countries with higher life expectancies.
Increased Awareness of Diabetic Complications: Rising awareness of the complications associated with uncontrolled diabetes, including neuropathic pain, is encouraging early diagnosis and treatment. Public health campaigns and improved patient education are driving greater demand for therapeutic interventions.
Government Support and Reimbursement Policies: Supportive government policies and reimbursement schemes for the treatment of diabetes-related complications are promoting the use of advanced therapies for diabetic neuropathic pain. These policies help make treatment more accessible, particularly in countries with strong healthcare systems.
Challenges
Side Effects of Pain Management Drugs: Many drugs used to manage diabetic neuropathic pain, such as antidepressants and anticonvulsants, come with significant side effects. These include dizziness, weight gain, and gastrointestinal issues, which can deter patients from continuing treatment.
High Cost of Advanced Therapies: While new therapies are proving effective, they can be expensive, limiting access for patients, especially in low- and middle-income countries. The cost of long-term treatment can be a significant burden on both patients and healthcare systems.
Lack of Early Diagnosis: Many cases of diabetic neuropathic pain go undiagnosed or are diagnosed late when nerve damage is already extensive. This delays the start of effective treatment, reducing the chances of preventing the progression of the condition.
Limited Availability of Specialised Care: In many regions, access to specialised care for diabetic neuropathic pain remains limited. A shortage of pain management specialists and inadequate healthcare infrastructure in developing countries restricts the availability of advanced treatments.
Patient Non-Adherence to Treatment: Non-adherence to treatment regimens is a common issue, especially when patients experience side effects or lack immediate relief from symptoms. Poor adherence can lead to worsening symptoms and reduced efficacy of long-term management strategies.
Future Opportunities
Development of Non-Pharmacological Treatments: There is growing interest in non-drug-based therapies, such as neuromodulation and physical therapy, which offer fewer side effects compared to traditional pharmacological treatments. These options present a significant growth opportunity for the market.
Personalised Medicine Approaches: Advances in genetic testing and biomarker research are paving the way for personalised medicine in the treatment of diabetic neuropathic pain. Tailoring treatments to individual patients’ genetic profiles could improve outcomes and reduce the trial-and-error approach to therapy.
Telemedicine and Remote Care: The rise of telemedicine offers a new avenue for managing diabetic neuropathic pain, particularly for patients in rural or underserved areas. Remote consultations and digital monitoring tools can help ensure consistent follow-up and adherence to treatment plans.
R&D in Novel Drug Therapies: Continuous research into novel drug therapies, including biologics and next-generation analgesics, presents significant growth potential. Companies investing in R&D for new treatments that are more effective and have fewer side effects are likely to gain a competitive advantage.
Diabetic Neuropathic Pain Market Trends
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
Diabetic Neuropathic Pain Market Segmentation
Market Breakup by Type
Peripheral Neuropathy
Autonomic Neuropathy
Proximal Neuropathy
Focal Neuropathy
Others
The market is divided into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy, and others. Peripheral neuropathy is the most common type, affecting the extremities and causing significant discomfort for patients. Autonomic Neuropathy impacts internal organs and functions, while proximal and focal neuropathies are less common but equally debilitating. These segments reflect the diverse nature of diabetic neuropathic pain, requiring targeted treatments.
Market Breakup by Treatment
Drugs
Others
Treatments for diabetic neuropathic pain include drugs such as analgesics, NSAIDs, antidepressants, and anticonvulsant drugs, as well as radiotherapy and other non-pharmacological approaches. Drug therapies remain the most widely used treatment option, but radiotherapy and emerging treatments offer alternatives for patients who do not respond to medication. The market is evolving to include a wider range of therapeutic options to meet varying patient needs.
Market Breakup by Route of Administration
Oral
Parenteral
Others
The market is segmented into oral, parenteral, and others. Oral administration is the most common route due to ease of use and patient compliance. Parenteral routes, including injections and infusions, are used for more severe cases requiring rapid pain relief. Other routes, such as transdermal patches, are gaining popularity for their ability to provide continuous, controlled pain relief without frequent dosing.
Market Breakup by End User
Hospitals and Clinics
Specialty Centers
Homecare Settings
Others
End users include hospitals and clinics, specialty centres, homecare settings, and others. Hospitals and clinics dominate the market as they provide comprehensive care, including diagnostics and treatment. Specialty centres focus on managing chronic conditions like diabetic neuropathic pain, while homecare settings are becoming more important as patients seek long-term, at-home management of their condition. Other end users include rehabilitation centres and outpatient care providers.
Market Breakup by Region
Diabetic Neuropathic Pain Market Competitive Landscape
The competitive landscape includes key players such as Pfizer, Inc., NeuroMetrix, Inc., GSK plc, Johnson & Johnson, Lupin, Astellas Pharma, Eli Lily and Company, Glenmark, Sun Pharmaceuticals Ltd, and Abbott. These companies are focusing on developing innovative drugs and therapies to manage diabetic neuropathic pain more effectively. Strategic partnerships, mergers, and acquisitions are common as these firms seek to strengthen their product portfolios and expand their presence in the market.
Key Questions Answered in the Report
What are the key drivers of the diabetic neuropathic pain market?
How are advances in pain management therapies influencing the market?
What challenges are faced by healthcare providers in treating diabetic neuropathic pain?
What are the most promising opportunities for market growth in emerging regions?
How is the shift towards non-opioid treatments impacting the market?
How are combination therapies changing the treatment landscape for diabetic neuropathic pain?
What role does telemedicine play in managing diabetic neuropathic pain?
What are the leading segments in the diabetic neuropathic pain market by treatment type?
How are pharmaceutical companies addressing the issue of drug side effects in pain management?
What are the key trends shaping the future of diabetic neuropathic pain treatments?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the diabetic neuropathic pain market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the diabetic neuropathic pain market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the diabetic neuropathic pain industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
The diabetic neuropathic pain market was valued at USD 4.3 billion in 2023 driven by the increasing demand for effective treatments that alleviate chronic pain and improve quality of life, alongside advancements in pain management therapies such as non-opioid drugs and neuromodulation devices. The market is projected to grow at a CAGR of 7.7% during the forecast period of 2024-2032, and likely to reach a market value of USD 8.5 billion by 2032.
Diabetic Neuropathic Pain Market Analysis
Diabetic neuropathic pain is a chronic and often debilitating condition caused by nerve damage resulting from prolonged high blood sugar levels in diabetic patients. It typically affects the feet, legs, and hands, and is characterised by burning, tingling, and sharp pain. This condition significantly impacts the quality of life, requiring long-term management through medications, physical therapy, and lifestyle adjustments.
Market Drivers
Rising Prevalence of Diabetes: The increasing prevalence of diabetes, particularly type 2 diabetes, is a major driver of the diabetic neuropathic pain market. As more people develop diabetes, the number of patients suffering from neuropathic complications is expected to rise, driving demand for effective treatments.
Advancements in Pain Management Therapies: Innovations in pain management, including the development of new drugs and non-invasive treatments, are contributing to market growth. Improved understanding of neuropathic pain pathways has led to more targeted therapies, enhancing treatment outcomes for diabetic neuropathic pain.
Growing Geriatric Population: The ageing population is more susceptible to diabetes and its complications, including neuropathic pain. As the elderly population increases, so too does the demand for effective treatments for diabetic neuropathic pain, particularly in developed countries with higher life expectancies.
Increased Awareness of Diabetic Complications: Rising awareness of the complications associated with uncontrolled diabetes, including neuropathic pain, is encouraging early diagnosis and treatment. Public health campaigns and improved patient education are driving greater demand for therapeutic interventions.
Government Support and Reimbursement Policies: Supportive government policies and reimbursement schemes for the treatment of diabetes-related complications are promoting the use of advanced therapies for diabetic neuropathic pain. These policies help make treatment more accessible, particularly in countries with strong healthcare systems.
Challenges
Side Effects of Pain Management Drugs: Many drugs used to manage diabetic neuropathic pain, such as antidepressants and anticonvulsants, come with significant side effects. These include dizziness, weight gain, and gastrointestinal issues, which can deter patients from continuing treatment.
High Cost of Advanced Therapies: While new therapies are proving effective, they can be expensive, limiting access for patients, especially in low- and middle-income countries. The cost of long-term treatment can be a significant burden on both patients and healthcare systems.
Lack of Early Diagnosis: Many cases of diabetic neuropathic pain go undiagnosed or are diagnosed late when nerve damage is already extensive. This delays the start of effective treatment, reducing the chances of preventing the progression of the condition.
Limited Availability of Specialised Care: In many regions, access to specialised care for diabetic neuropathic pain remains limited. A shortage of pain management specialists and inadequate healthcare infrastructure in developing countries restricts the availability of advanced treatments.
Patient Non-Adherence to Treatment: Non-adherence to treatment regimens is a common issue, especially when patients experience side effects or lack immediate relief from symptoms. Poor adherence can lead to worsening symptoms and reduced efficacy of long-term management strategies.
Future Opportunities
Development of Non-Pharmacological Treatments: There is growing interest in non-drug-based therapies, such as neuromodulation and physical therapy, which offer fewer side effects compared to traditional pharmacological treatments. These options present a significant growth opportunity for the market.
Personalised Medicine Approaches: Advances in genetic testing and biomarker research are paving the way for personalised medicine in the treatment of diabetic neuropathic pain. Tailoring treatments to individual patients’ genetic profiles could improve outcomes and reduce the trial-and-error approach to therapy.
Telemedicine and Remote Care: The rise of telemedicine offers a new avenue for managing diabetic neuropathic pain, particularly for patients in rural or underserved areas. Remote consultations and digital monitoring tools can help ensure consistent follow-up and adherence to treatment plans.
R&D in Novel Drug Therapies: Continuous research into novel drug therapies, including biologics and next-generation analgesics, presents significant growth potential. Companies investing in R&D for new treatments that are more effective and have fewer side effects are likely to gain a competitive advantage.
Diabetic Neuropathic Pain Market Trends
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
- Growing Preference for Non-Opioid Treatments
- Increasing Use of Combination Therapies
- Rising Focus on Personalised Medicine
- Adoption of Digital Health Solutions
- Advancements in Neuromodulation Technologies
- Focus on Early Diagnosis and Preventive Care
Diabetic Neuropathic Pain Market Segmentation
Market Breakup by Type
Peripheral Neuropathy
Autonomic Neuropathy
Proximal Neuropathy
Focal Neuropathy
Others
The market is divided into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy, and others. Peripheral neuropathy is the most common type, affecting the extremities and causing significant discomfort for patients. Autonomic Neuropathy impacts internal organs and functions, while proximal and focal neuropathies are less common but equally debilitating. These segments reflect the diverse nature of diabetic neuropathic pain, requiring targeted treatments.
Market Breakup by Treatment
Drugs
- Analgesics
- NSAIDs
- Antidepressants
- Anticonvulsant Drugs
- Others
Others
Treatments for diabetic neuropathic pain include drugs such as analgesics, NSAIDs, antidepressants, and anticonvulsant drugs, as well as radiotherapy and other non-pharmacological approaches. Drug therapies remain the most widely used treatment option, but radiotherapy and emerging treatments offer alternatives for patients who do not respond to medication. The market is evolving to include a wider range of therapeutic options to meet varying patient needs.
Market Breakup by Route of Administration
Oral
Parenteral
Others
The market is segmented into oral, parenteral, and others. Oral administration is the most common route due to ease of use and patient compliance. Parenteral routes, including injections and infusions, are used for more severe cases requiring rapid pain relief. Other routes, such as transdermal patches, are gaining popularity for their ability to provide continuous, controlled pain relief without frequent dosing.
Market Breakup by End User
Hospitals and Clinics
Specialty Centers
Homecare Settings
Others
End users include hospitals and clinics, specialty centres, homecare settings, and others. Hospitals and clinics dominate the market as they provide comprehensive care, including diagnostics and treatment. Specialty centres focus on managing chronic conditions like diabetic neuropathic pain, while homecare settings are becoming more important as patients seek long-term, at-home management of their condition. Other end users include rehabilitation centres and outpatient care providers.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Diabetic Neuropathic Pain Market Competitive Landscape
The competitive landscape includes key players such as Pfizer, Inc., NeuroMetrix, Inc., GSK plc, Johnson & Johnson, Lupin, Astellas Pharma, Eli Lily and Company, Glenmark, Sun Pharmaceuticals Ltd, and Abbott. These companies are focusing on developing innovative drugs and therapies to manage diabetic neuropathic pain more effectively. Strategic partnerships, mergers, and acquisitions are common as these firms seek to strengthen their product portfolios and expand their presence in the market.
Key Questions Answered in the Report
What are the key drivers of the diabetic neuropathic pain market?
How are advances in pain management therapies influencing the market?
What challenges are faced by healthcare providers in treating diabetic neuropathic pain?
What are the most promising opportunities for market growth in emerging regions?
How is the shift towards non-opioid treatments impacting the market?
How are combination therapies changing the treatment landscape for diabetic neuropathic pain?
What role does telemedicine play in managing diabetic neuropathic pain?
What are the leading segments in the diabetic neuropathic pain market by treatment type?
How are pharmaceutical companies addressing the issue of drug side effects in pain management?
What are the key trends shaping the future of diabetic neuropathic pain treatments?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the diabetic neuropathic pain market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the diabetic neuropathic pain market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the diabetic neuropathic pain industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Diabetic Neuropathic Pain Market Overview – 8 Major Markets
- 3.1 Diabetic Neuropathic Pain Market Historical Value (2017-2023)
- 3.2 Diabetic Neuropathic Pain Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Diabetic Neuropathic Pain Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Diabetic Neuropathic Pain Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Diabetic Neuropathic Pain Market Landscape – 8 Major Markets
- 8.1 Diabetic Neuropathic Pain Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Diabetic Neuropathic Pain Market: Product Landscape
- 8.2.1 Analysis by Treatment
- 8.2.2 Analysis by Route of Administration
- 9 Diabetic Neuropathic Pain Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Diabetic Neuropathic Pain Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Diabetic Neuropathic Pain Market Segmentation (2018-2034) - 8 Major Markets
- 12.1 Diabetic Neuropathic Pain Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 Peripheral Neuropathy
- 12.1.3 Autonomic Neuropathy
- 12.1.4 Proximal Neuropathy
- 12.1.5 Focal Neuropathy
- 12.1.6 Others
- 12.2 Diabetic Neuropathic Pain Market (2018-2034) by Treatment
- 12.2.1 Market Overview
- 12.2.2 Drugs
- 12.2.2.1 Analgesics
- 12.2.2.2 NSAIDs
- 12.2.2.3 Antidepressants
- 12.2.2.4 Anticonvulsant Drugs
- 12.2.2.5 Others
- 12.2.3 Radiotherapy
- 12.2.4 Others
- 12.3 Diabetic Neuropathic Pain Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Parenteral
- 12.3.4 Others
- 12.4 Diabetic Neuropathic Pain Market (2018-2034) by End User
- 12.4.1 Market Overview
- 12.4.2 Hospitals & Clinics
- 12.4.3 Specialty Centers
- 12.4.4 Homecare Settings
- 12.4.5 Others
- 12.5 Diabetic Neuropathic Pain Market (2018-2034) by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 EU-4 and the United Kingdom
- 12.5.3.1 Germany
- 12.5.3.2 France
- 12.5.3.3 Italy
- 12.5.3.4 Spain
- 12.5.3.5 United Kingdom
- 12.5.4 Japan
- 12.5.5 India
- 13 United States Diabetic Neuropathic Pain Market (2018-2034)
- 13.1 United States Diabetic Neuropathic Pain Market Historical Value (2017-2023)
- 13.2 United States Diabetic Neuropathic Pain Market Forecast Value (2024-2032)
- 13.3 United States Diabetic Neuropathic Pain Market (2018-2034) by Type
- 13.3.1 Market Overview
- 13.3.2 Peripheral Neuropathy
- 13.3.3 Autonomic Neuropathy
- 13.3.4 Proximal Neuropathy
- 13.3.5 Focal Neuropathy
- 13.3.6 Others
- 13.4 United States Diabetic Neuropathic Pain Market (2018-2034) by Treatment
- 13.4.1 Market Overview
- 13.4.2 Drugs
- 13.4.2.1 Analgesics
- 13.4.2.2 NSAIDs
- 13.4.2.3 Antidepressants
- 13.4.2.4 Anticonvulsant Drugs
- 13.4.2.5 Others
- 13.4.3 Radiotherapy
- 13.4.4 Others
- 13.5 United States Diabetic Neuropathic Pain Market (2018-2034) by Route of Administration
- 13.5.1 Market Overview
- 13.5.2 Oral
- 13.5.3 Parenteral
- 13.5.4 Others
- 13.6 United States Diabetic Neuropathic Pain Market (2018-2034) by End User
- 13.6.1 Market Overview
- 13.6.2 Hospitals & Clinics
- 13.6.3 Specialty Centers
- 13.6.4 Homecare Settings
- 13.6.5 Others
- 14 EU-4 and United Kingdom Diabetic Neuropathic Pain Market (2018-2034)
- 14.1 EU-4 and United Kingdom Diabetic Neuropathic Pain Market Historical Value (2017-2023)
- 14.2 EU-4 and United Kingdom Diabetic Neuropathic Pain Market Forecast Value (2024-2032)
- 14.3 EU-4 and United Kingdom Diabetic Neuropathic Pain Market (2018-2034) by Type
- 14.3.1 Market Overview
- 14.3.2 Peripheral Neuropathy
- 14.3.3 Autonomic Neuropathy
- 14.3.4 Proximal Neuropathy
- 14.3.5 Focal Neuropathy
- 14.3.6 Others
- 14.4 EU-4 and United Kingdom Diabetic Neuropathic Pain Market (2018-2034) by Treatment
- 14.4.1 Market Overview
- 14.4.2 Drugs
- 14.4.2.1 Analgesics
- 14.4.2.2 NSAIDs
- 14.4.2.3 Antidepressants
- 14.4.2.4 Anticonvulsant Drugs
- 14.4.2.5 Others
- 14.4.3 Radiotherapy
- 14.4.4 Others
- 14.5 EU-4 and United Kingdom Diabetic Neuropathic Pain Market (2018-2034) by Route of Administration
- 14.5.1 Market Overview
- 14.5.2 Oral
- 14.5.3 Parenteral
- 14.5.4 Others
- 14.6 EU-4 and United Kingdom Diabetic Neuropathic Pain Market (2018-2034) by End User
- 14.6.1 Market Overview
- 14.6.2 Hospitals & Clinics
- 14.6.3 Specialty Centers
- 14.6.4 Homecare Settings
- 14.6.5 Others
- 15 Japan Diabetic Neuropathic Pain Market
- 15.1 Japan Diabetic Neuropathic Pain Market Historical Value (2017-2023)
- 15.2 Japan Diabetic Neuropathic Pain Market Forecast Value (2024-2032)
- 15.3 Japan Diabetic Neuropathic Pain Market (2018-2034) by Type
- 15.3.1 Market Overview
- 15.3.2 Peripheral Neuropathy
- 15.3.3 Autonomic Neuropathy
- 15.3.4 Proximal Neuropathy
- 15.3.5 Focal Neuropathy
- 15.3.6 Others
- 15.4 Japan Diabetic Neuropathic Pain Market (2018-2034) by Treatment
- 15.4.1 Market Overview
- 15.4.2 Drugs
- 15.4.2.1 Analgesics
- 15.4.2.2 NSAIDs
- 15.4.2.3 Antidepressants
- 15.4.2.4 Anticonvulsant Drugs
- 15.4.2.5 Others
- 15.4.3 Radiotherapy
- 15.4.4 Others
- 15.5 Japan Diabetic Neuropathic Pain Market (2018-2034) by Route of Administration
- 15.5.1 Market Overview
- 15.5.2 Oral
- 15.5.3 Parenteral
- 15.5.4 Others
- 15.6 Japan Diabetic Neuropathic Pain Market (2018-2034) by End User
- 15.6.1 Market Overview
- 15.6.2 Hospitals & Clinics
- 15.6.3 Specialty Centers
- 15.6.4 Homecare Settings
- 15.6.5 Others
- 16 India Diabetic Neuropathic Pain Market
- 16.1 India Diabetic Neuropathic Pain Market Historical Value (2017-2023)
- 16.2 India Diabetic Neuropathic Pain Market Forecast Value (2024-2032)
- 16.3 India Diabetic Neuropathic Pain Market (2018-2034) by Type
- 16.3.1 Market Overview
- 16.3.2 Peripheral Neuropathy
- 16.3.3 Autonomic Neuropathy
- 16.3.4 Proximal Neuropathy
- 16.3.5 Focal Neuropathy
- 16.3.6 Others
- 16.4 India Diabetic Neuropathic Pain Market (2018-2034) by Treatment
- 16.4.1 Market Overview
- 16.4.2 Drugs
- 16.4.2.1 Analgesics
- 16.4.2.2 NSAIDs
- 16.4.2.3 Antidepressants
- 16.4.2.4 Anticonvulsant Drugs
- 16.4.2.5 Others
- 16.4.3 Radiotherapy
- 16.4.4 Others
- 16.5 India Diabetic Neuropathic Pain Market (2018-2034) by Route of Administration
- 16.5.1 Market Overview
- 16.5.2 Oral
- 16.5.3 Parenteral
- 16.5.4 Others
- 16.6 India Diabetic Neuropathic Pain Market (2018-2034) by End User
- 16.6.1 Market Overview
- 16.6.2 Hospitals & Clinics
- 16.6.3 Specialty Centers
- 16.6.4 Homecare Settings
- 16.6.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Treatment Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Treatment Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 Pfizer, Inc.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Companies News and Developments
- 23.2.5 Certifications
- 23.3 NeuroMetrix, Inc.
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Companies News and Developments
- 23.3.5 Certifications
- 23.4 GSK plc
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Companies News and Developments
- 23.4.5 Certifications
- 23.5 Johnson & Johnson
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Companies News and Developments
- 23.5.5 Certifications
- 23.6 Lupin
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Companies News and Developments
- 23.6.5 Certifications
- 23.7 Astellas Pharma
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Companies News and Developments
- 23.7.5 Certifications
- 23.8 Eli Lily and Company
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Companies News and Developments
- 23.8.5 Certifications
- 23.9 Glenmark
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Companies News and Developments
- 23.9.5 Certifications
- 23.10 Sun Pharmaceuticals Ltd
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Companies News and Developments
- 23.10.5 Certifications
- 23.11 Abbott
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Companies News and Developments
- 23.11.5 Certifications
- 24 Diabetic Neuropathic Pain Treatment Drugs - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- *The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.